drugset / Trial / NCT00337545
Phase II Trial of RAD001 in Refractory Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
Timeline
- Start
- 2006-05
- Primary completion
- —
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | Oral |